UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant radiographic ...

Paul E. Dato, MD, discusses how a 63-year-old Black man with recurrent hormone-sensitive prostate cancer (HSPC) presented with high-grade disease and multiple metastases after initial prostatectomy, ...

The risk of stricture formation was 4.6% in the TFL cohort vs 2.4% in the holmium laser cohort. While the rate of ureteral strictures following ureteroscopic laser lithotripsy is low, the incidence ...

The AI tool outperformed MRI in assessing for SVI. Unfold AI, an artificial intelligence (AI)-based risk mapping tool, was able to accurately predict seminal vesicle invasion (SVI) in patients with ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively. Dr Shore explained the ...

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Alex Tatem, MD, a urologist with Urology of Indiana and corporate director of men’s health for US Urology Partners, for ...

Current 2025 guidelines recommend ADT with intensification. Multiple intensification options include abiraterone, darolutamide, and docetaxel. Key clinical trials include ARANOTE, ARASENS, and TITAN.

Promontory Therapeutics will initiate a phase 3 trial of PT-112 for mCRPC following a positive FDA meeting. PT-112 induces immunogenic cancer cell death and targets bone disease sites, with ...

The AMPLIFY trial evaluates 64Cu-SAR-bisPSMA's efficacy in detecting prostate cancer lesions in patients with biochemical recurrence. 64Cu-SAR-bisPSMA has received FDA fast track designation for PET ...

The first successful human bladder transplant was performed by USC and UCLA surgeons, marking a significant medical milestone. The patient, previously on dialysis, showed immediate improvement ...